Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report.

Abstract

We describe the results of an open-label study designed to assess the effectiveness and tolerability of aripiprazole addition to an antidepressant in patients with major depressive disorder with postpartum onset who had not experienced significant clinical improvement following an adequate trial of an antidepressant. Eight of ten women completed the trial with augmentation of aripiprazole (2-10 mg) to their existing antidepressant treatment. Our results suggest a possible therapeutic role for aripiprazole when added to an antidepressant in non-breastfeeding women with postpartum depression. Aripiprazole addition appeared effective and safe with no serious adverse events reported.

• Authors: Verinder Sharma, Christina Sommerdyk, Bin Xie
• Journal: Archives of women's mental health (Arch Womens Ment Health) Vol. 18 Issue 1 Pg. 131-4 (Feb 2015) ISSN: 1435-1102 [Electronic] Austria
• PMID: 25223952 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antidepressive Agents
• Antipsychotic Agents
• Piperazines
• Quinolones
• Aripiprazole

Topics

• Adult
• Antidepressive Agents (therapeutic use)
• Antipsychotic Agents (therapeutic use)
• Aripiprazole
• Depression, Postpartum (drug therapy)
• Depressive Disorder, Major (drug therapy)
• Drug Therapy, Combination
• Female
• Humans
• Piperazines (therapeutic use)
• Psychiatric Status Rating Scales
• Quinolones (therapeutic use)
• Treatment Outcome